Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind Phase 2 trial of Brenipatide in adults with moderate-to-severe COPD
CTR20263107Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of brenipatide in chronic obstructive pulmonary disease (COPD), sponsored by Eli Lilly and Company. Started Aug 2026; status: active.
02
Drugs
brenipatide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20263107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263107.